ENTA Enanta Pharmaceuticals
- 12.930
- +0.170+1.33%
- 12.970
- +0.040+0.31%
Enanta Pharmaceuticals News
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably feeling a little disappointed, since its shares fell 8.3% to US$12.76 in the week after its latest quarterly results. Revenue
Enanta Pharmaceuticals | 10-Q: Quarterly report
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Enanta Pharmaceuticals Price Target Cut to $27.00/Share From $28.00 by HC Wainwright & Co.
Enanta Pharmaceuticals Price Target Cut to $27.00/Share From $28.00 by HC Wainwright & Co.
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
J.P. Morgan Securities: Maintaining the Enanta Pharma (ENTA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $23.00 to $22.00.
J.P. Morgan Securities: Maintaining the Enanta Pharma (ENTA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $23.00 to $22.00.
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $22
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and lowers the price target from $23 to $22.
Enanta Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 67.81% JMP Securities $23 → $22 Maintains Market Outperform 02/08/2024 -16.09% JP Morgan $12 →
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Earnings Call Summary | Enanta Pharmaceuticals(ENTA.US) Q2 2024 Earnings Conference
The following is a summary of the Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript:Financial Performance:Enanta reported total Q2 revenue of $17.1 million from royalty revenue on A
Analysts' Top Healthcare Picks: OrthoPediatrics (KIDS), Enanta Pharmaceuticals (ENTA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--May 7, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, Vs. Street Est of $16.2M
04:04 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M
Enanta Pharmaceuticals 2Q Loss $31.2M >ENTA
Enanta Pharmaceuticals 2Q Loss $31.2M >ENTA
Enanta Pharma Q2 2024 Earnings Preview
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 30, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virolo
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 30, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virolo
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 P.m. ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2024
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virol
Analysis
Price Target
No Data
